NasdaqGM:CRSPBiotechs
CRISPR Therapeutics (CRSP): Reassessing Valuation After a 13% Pullback and Strong Year‑to‑Date Gains
CRISPR Therapeutics (CRSP) has quietly pulled back over the past 3 months, even though the stock is still up sharply year to date. That disconnect is what makes the setup interesting now.
See our latest analysis for CRISPR Therapeutics.
After a strong run earlier in the year, the recent 90 day share price return of minus 13.03 percent and cooler short term moves suggest momentum is fading a bit. However, the year to date share price return of 32.13 percent and a 12 month total shareholder...